JP2006528949A5 - - Google Patents

Download PDF

Info

Publication number
JP2006528949A5
JP2006528949A5 JP2006529827A JP2006529827A JP2006528949A5 JP 2006528949 A5 JP2006528949 A5 JP 2006528949A5 JP 2006529827 A JP2006529827 A JP 2006529827A JP 2006529827 A JP2006529827 A JP 2006529827A JP 2006528949 A5 JP2006528949 A5 JP 2006528949A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
agent
patients
therapeutic agent
valsartan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006529827A
Other languages
English (en)
Japanese (ja)
Other versions
JP4783733B2 (ja
JP2006528949A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/005204 external-priority patent/WO2004101535A1/en
Publication of JP2006528949A publication Critical patent/JP2006528949A/ja
Publication of JP2006528949A5 publication Critical patent/JP2006528949A5/ja
Application granted granted Critical
Publication of JP4783733B2 publication Critical patent/JP4783733B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006529827A 2003-05-16 2004-05-14 バルサルタンを含む医薬組成物 Expired - Fee Related JP4783733B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47113703P 2003-05-16 2003-05-16
US60/471,137 2003-05-16
PCT/EP2004/005204 WO2004101535A1 (en) 2003-05-16 2004-05-14 Pharmaceutical composition comprising valsartan

Publications (3)

Publication Number Publication Date
JP2006528949A JP2006528949A (ja) 2006-12-28
JP2006528949A5 true JP2006528949A5 (cg-RX-API-DMAC7.html) 2007-06-28
JP4783733B2 JP4783733B2 (ja) 2011-09-28

Family

ID=33452429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006529827A Expired - Fee Related JP4783733B2 (ja) 2003-05-16 2004-05-14 バルサルタンを含む医薬組成物

Country Status (10)

Country Link
US (2) US20070054947A1 (cg-RX-API-DMAC7.html)
EP (1) EP1631556A1 (cg-RX-API-DMAC7.html)
JP (1) JP4783733B2 (cg-RX-API-DMAC7.html)
CN (1) CN1816533A (cg-RX-API-DMAC7.html)
AU (2) AU2004238546A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0410374A (cg-RX-API-DMAC7.html)
CA (1) CA2525665A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05012299A (cg-RX-API-DMAC7.html)
TW (1) TW200509909A (cg-RX-API-DMAC7.html)
WO (1) WO2004101535A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1951309A2 (en) * 2005-11-08 2008-08-06 Novartis AG Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2012063254A1 (en) * 2010-11-12 2012-05-18 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
JPWO2013147137A1 (ja) * 2012-03-30 2015-12-14 味の素株式会社 心不全の治療剤
RU2667643C2 (ru) 2012-08-24 2018-09-21 Новартис Аг Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
DK3626270T3 (da) * 2013-08-26 2024-01-15 Novartis Ag Behandling af kardiovaskulære sygdomme
CN106414416B (zh) * 2014-09-09 2020-03-27 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
CA3103599A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
CN112955965B (zh) * 2018-06-14 2024-04-09 阿斯利康(英国)有限公司 使用二氢吡啶类钙通道阻断剂医药组合物降低血压的方法
CN115317478B (zh) * 2022-08-26 2023-05-02 宁波大学 沙库巴曲缬沙坦类物质在制备药物成瘾和复吸药物的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
KR20040078140A (ko) * 1998-07-10 2004-09-08 노파르티스 아게 발사르탄 및 칼슘 채널 차단제의 항고혈압 병용 제제
US6596747B2 (en) * 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
WO2000047207A1 (en) * 1999-02-09 2000-08-17 Bristol-Myers Squibb Company LACTAM INHIBITORS OF FXa AND METHOD
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
EP1332131A2 (en) * 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
WO2002053161A1 (en) * 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
US6395782B1 (en) * 2001-03-02 2002-05-28 Wisconsin Alumni Research Foundation Method of increasing longevity and preventing body weight wasting in autoimmune disease by using conjugated linoleic acid
WO2002096363A2 (en) * 2001-05-30 2002-12-05 Alteon, Inc. Method for treating fibrotic diseases or other indications
CN1571668A (zh) * 2001-10-18 2005-01-26 诺瓦提斯公司 At1-受体拮抗剂和心血管药物形成的盐
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds

Similar Documents

Publication Publication Date Title
JP2015512406A5 (cg-RX-API-DMAC7.html)
JP3018160B2 (ja) 月経困難症及び/又は月経前症候群の軽減用薬剤
US9034909B2 (en) Use of organic compound for the treatment of Noonan Syndrome
ES2671926T3 (es) Comprimido recubierto en seco que contiene tegafur, gimeracilo y oteracilo potásico
US20100168238A1 (en) Pharmaceutical composition containing phloroglucinol and paracetamol
EP4344701A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
TW200911247A (en) Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for preparing a medicament for use in the treatment of motor disorders related to parkinson's disease
RU2002115814A (ru) Лечение системной красной волчанки с помощью дегидроэпиандростерона
TW202606681A (zh) 紫質症之預防或治療劑
JPH02138123A (ja) 心不全治療用医薬組成物
CZ79593A3 (en) Antitussive preparation
JP2010163426A (ja) ホスホジエステラーゼ5阻害剤とアルギニンを含有する医薬組成物
JP2011093890A (ja) 鼻汁分泌抑制用組成物
JPS6058726B2 (ja) プリン誘導体を有効成分として含有する抗アレルギ−,鎮痛,鎮静剤
KR100379155B1 (ko) 새로운 진통제 조성물
EP3790550A1 (en) Pharmaceutical composition and method for acute on chronic liver failure
US3073744A (en) Therapeutic compositions against virus diseases
JP2026516115A (ja) 胃食道逆流症(GERD)を治療するためのリナプラザングルレート(linaprazan glurate)
JP2621382B2 (ja) 尿酸排泄剤
JPS6116A (ja) 有機化合物に関する改良
JP3254712B2 (ja) 医薬組成物
Upadhyay Studies on Formulation and optimization of Gastro Retentive multi-Particulates of Glibenclamide and Metformin hydrochloride for the treatment of Type II…
JPH05262747A (ja) 潰瘍性大腸炎治療剤
TW202615028A (zh) 錠劑配方
JP2024521354A5 (ja) 多剤混合薬又は医薬組成物